Kinsey Shultz Piatz, MD
Family Medicine · Rapid City, SDNPI 1770598427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$686
- Lilly USA, LLC$608
- AbbVie$523
- Boehringer Ingelheim$383
- Pfizer$312
- plus $1K from 15 others
What the payments were for
- Food & beverage$5,149100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 81 | $1,203 |
| AstraZeneca | 38 | $686 |
| Lilly USA, LLC | 39 | $608 |
| AbbVie(2 entities) | 28 | $523 |
| Boehringer Ingelheim | 27 | $383 |
| Pfizer | 17 | $312 |
| Exact Sciences | 16 | $303 |
| Novo Nordisk | 14 | $266 |
| E.r. Squibb & Sons, L.L.C. | 10 | $172 |
| Johnson & Johnson | 7 | $113 |
| Astellas Pharma US Inc | 5 | $105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $94 |
| GSK | 6 | $91 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Merck | 4 | $57 |
| Eisai Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Bayer | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
How this compares
$5,149 in reported general payments places this provider in the 95th percentile of 408 family medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $46,288 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $19,173 |
| FarxigaDapagliflozin Propanediol | 12 | $18,767 |
| MounjaroTirzepatide | 12 | $11,667 |
| OzempicSemaglutide | 11 | $10,106 |
| SynthroidLevothyroxine Sodium | 42 | $2,653 |
| Losartan Potassium | 227 | $2,422 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,271 |
| Rosuvastatin Calcium | 160 | $2,143 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,963 |
| Metoprolol Succinate | 112 | $1,586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,371 |
| Levothyroxine Sodium | 169 | $1,365 |
| Atorvastatin Calcium | 145 | $1,328 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 13 | $1,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $312 | $46,28833 claims |
| GSKTrelegy Ellipta | $91 | $19,17311 claims |
| AstraZenecaFarxiga | $686 | $18,76712 claims |
| Lilly USA, LLCMounjaro | $608 | $11,66712 claims |
| Novo NordiskOzempic | $266 | $10,10611 claims |
| AbbVieSynthroid | $523 | $2,65342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 family medicine providers in South Dakota.
Other family medicine in Rapid City
- Kyla Helm-SwansonRapid City$22K
- Kay KeltsRapid City$5K
- Egon DzintarsRapid City$4K
- Erika ToyodaRapid City$2K
- Carol ZielikeRapid City$2K
- Lorelee StockRapid City$2K
- Andrew BurchettSioux Falls$13K
- Lornell HansenSioux Falls$11K
- Michael GerlachMitchell$9K
- Jeffry MeyerSioux Falls$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.